Zelluna Asa · OSL:ZLNA
Zelluna Asa — Ultimovacs — Q4 2021 Earnings Presentation
27 slides from Zelluna Asa's earnings presentation, Feb 17, 2022
Slide 1: Fourth Quarter 2021 Presentation
Fourth Quarter 2021 Presentation 17 February 2022 Carlos de Sousa, CEO Jens Bjørheim, CMO Hans Vassgård Eid, CFO
Slide 2: Forward-looking statements disclaimer
This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Ultimovacs’ business, financial condition and results of opera
Slide 3: Non-Confidential, Ultimovacs copy and distribution rights
Non-Confidential, Ultimovacs copy and distribution rights
Slide 4: Good clinical progress with increased patient enrollment rate in INITIUM and NIPU
• Good clinical progress with increased patient enrollment rate in INITIUM and NIPU • Ultimovacs has coped well with the challenges caused by Covid-19 – minor adjustments in the guidance on topline readout for INITIUM and NIPU • FDA Fast Track and Orphan Drug Designations received for UV1 in the lea
Slide 5: Enrollment updates in quarterly reports
• • • • Ultimovacs will continue to provide enrollment updates in each quarterly report. Although we remain optimistic regarding progress in our broad clinical program, the effect of the pandemic on the biotech industry and the conduct of clinical trials is still uncertain. Non-Confidential, Ultimov
Slide 6: Non-Confidential, Ultimovacs copy and distribution rights
• • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 7: Non-Confidential, Ultimovacs copy and distribution rights
• • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 8: New Phase II trial in NSCLC and successful capital raise
New Phase II trial in NSCLC announced in October 2021 • UV1 to be investigated in combination with pembrolizumab • • Successful Capital Raise • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 9: Non-Confidential, Ultimovacs copy and distribution rights
• • • • • • • • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 10: Non-Confidential, Ultimovacs copy and distribution rights
• • • • • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 11: Non-Confidential, Ultimovacs copy and distribution rights
Non-Confidential, Ultimovacs copy and distribution rights
Slide 12: Phase I trials of UV1 with ipilimumab and pembrolizumab
• Good safety profile supporting use of UV1 in combination • Good safety profile supporting use of UV1 in combination with with ipilimumab pembrolizumab • Consistent set of data showing strong initial signals of ‐ clinical response • Results were published in Frontiers in Immunology in • Consistent
Slide 13: Response rates, PFS and OS in cohorts 1 and 2
• The Response Rates for the 30 patients in cohort 1 and cohort 2 combined, as measured by iRECIST: • • • • • Median Progression Free Survival (mPFS): • • • • Overall Survival (OS): • • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 14: INITIUM Phase II trial in malignant melanoma
INITIUM • INITIUM: Phase II combination trial with nivolumab and ipilimumab in malignant melanoma Non-Confidential, Ultimovacs copy and distribution rights
Slide 15: UV1 clinical trial program by indication and phase
Pre- Indication Clinical trial information Phase I Phase II Phase III Contributors clinical First line metastatic malignant melanoma First line metastatic With malignant melanoma Second line mesothelioma Second line ovarian cancer First line head and neck cancer First line NSCLC Prostate cancer Non-
Slide 16: June 2020 16 February 2022 16 February 2022
• • • • • • • • June 2020 • 16 February 2022 • 16 February 2022 • be updated with the Q4 2022 • report patients have progressed or died Non-Confidential, Ultimovacs copy and distribution rights
Slide 17: 16 February 2022 be updated with the Q4 2022 report
• • • • • • • • • 16 February 2022 • be updated with the Q4 2022 • report be updated with the Q4 2022 report Non-Confidential, Ultimovacs copy and distribution rights
Slide 18: Non-Confidential, Ultimovacs copy and distribution rights
• ‐ ‐ • ‐ ‐ ‐ • Non-Confidential, Ultimovacs copy and distribution rights
Slide 19: Non-Confidential, Ultimovacs copy and distribution rights
Non-Confidential, Ultimovacs copy and distribution rights
Slide 20: Non-Confidential, Ultimovacs copy and distribution rights
• • • • • • • • Non-Confidential, Ultimovacs copy and distribution rights
Slide 21: Key financials per Q4-2021 - Ultimovacs Group
Key financials per Q4-2021 - Ultimovacs Group NOK (000) Q4-20 0 Q4-21 FY20 FY21 Total revenues - - - - ▪ 0 Payroll and payroll related expenses 14 662 11 885 50 989 61 916 External R&D and IPR expenses (incl. grants) 7 537 35 538 60 870 88 169 Other operating expenses (incl. depreciation) 3 390 3 50
Slide 22: Non-Confidential, Ultimovacs copy and distribution rights
• Non-Confidential, Ultimovacs copy and distribution rights
Slide 23: Key financials per Q4-2021 - Ultimovacs Group
Key financials per Q4-2021 - Ultimovacs Group NOK (000) Q1-20 Q2-20 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 Q4-21 Total revenues - - - - - - - - Payroll and payroll related expenses 10 015 13 197 13 115 14 662 12 203 14 514 23 314 11 885 External R&D and IPR expenses (incl. grants) 18 089 19 938 15 307 7 537
Slide 24: Non-Confidential, Ultimovacs copy and distribution rights
Non-Confidential, Ultimovacs copy and distribution rights
Slide 25: Good clinical progress with increased patient enrollment rate in INITIUM and NIPU
• Good clinical progress with increased patient enrollment rate in INITIUM and NIPU • Ultimovacs has coped well with the challenges caused by Covid-19 • minor adjustments in the guidance on topline readout for INITIUM and NIPU • New Phase II trial in NSCLC • a further extension of the broad UV1 Phas
Slide 26: Q&A
Slide 27: Ultimovacs contact details
> ultimovacs Enabling the Immune System to Fight Cancer For questions Carlos de Sousa, CEO Anne Worsge, Head of IR carlos.desousa@ultimovacs.com ir@ultimovacs.com +47 908 92507 +47 906 86815 www.ultimovacs.com